Gene therapy may slow progression of a life-threatening cardiac ailment: Study

A new study in mice suggests that gene therapy targeting plakophilin-2 can improve survival in people with arrhythmogenic right ventricular cardiomyopathy (ARVC). ARVC is a rare inherited disorder in which the heart's walls weaken, leading to irregular heartbeats. The study found that mice treated with gene therapy lived longer and had a reduction in fibrous tissue buildup.